Determination of the reference value of the incremental cost-efficacy and cost-utility coefficient in Russia in oncology

The share of antineoplastic drug dossiers submitted to reimbursement in Russia raised from 15% in 2014 to 28% in 2017. The effectiveness and safety of innovative anti-cancer therapy is higher comparing to widely used traditional treatments. At the mean time the costs of innovative anti-cancer care are much higher, which request the incremental costs calculation. Aim. To determine the refence value of incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR). Materials and methods. We analyzed health-economic (HE) studies submitted in the drug dossiers with ATC codes L01 and L02 to the reimbursement in Russia in 2014-2017. Life-years gained (LYG), cost of one LYG and cost of one quality adjusted life-year (QALY) gained we taken from HE studies. Subgroups of drugs included and not included in the reimbursement were compared. The reference cost of one LYG was calculated. Results. The median and geometric mean value of ICER/LYG and ICUR/QALY in the subgroup of drugs included in the reimbursement are 2 335 076 RUR/LYG and 2 343 954 RUR/QALY, consequently. Median and geometric mean of ICER/LYG in the subgroup of drugs included and in the reimbursement are by 33% and 21% lower comparing to the subgroup of drugs not included in the reimbursement. Median and geometric mean of cost of one QALY gained is 2 324 906 RUR/QALY. Conclusion. The reference value of ICER/LYG and ICUR is in the interval 2 300 000 - 2 500 000 RUR.